Zhengda Tianqing's parent company's performance is amazing, and its profit in 2018 has increased more than three times in advance!

On March 20, China biopharma, the parent company of Chia Tai Tianqing, announced that it is expected that the group's profit in 2018 will increase significantly compared with that in 2017, and the profit attributable to the holders of the parent company in 2018 will increase to between 8.908 billion yuan and 9.284 billion yuan (2017: About 2.171 billion yuan), with a year-on-year growth of about 310.3% - 327.6% China's biopharmaceutical industry has a strong strength, mainly engaged in research, development, production and sales of modern Chinese medicine preparations, biopharmaceuticals and chemicals In 2016 and 2017, it was ranked among the top 50 best companies in Asia Pacific of Forbes Asia Many of its companies are also among the best in the domestic pharmaceutical industry, such as Zhengda Tianqing Pharmaceutical Co., Ltd., Beijing Taide Pharmaceutical Co., Ltd., Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd Among them, the R & D center of Zhengda Tianqing is the postdoctoral research station, and the only new liver disease drug Engineering Technology Research Center in China In 2012, Beijing Taide obtained GMP approval from Japan's Ministry of health, labor and welfare China is rich in biopharmaceutical products, including a variety of biopharmaceuticals and chemicals, which are in a strong position in many potential treatment fields, such as tumor, liver disease, cardio cerebrovascular disease, analgesia, respiratory system medicine, orthopedic diseases, etc According to the company's development, the drugs with the most potential development are as follows: China biopharmaceutical has been focusing on drug research and development In the first half of 2018, the R & D investment reached RMB 1328.18 million, accounting for 13.7% of the revenue With high investment and strong strength, its R & D performance is not poor, and the competitiveness of new drugs and consistency evaluation is full 1 The heavyweight innovative drug androtinib hydrochloride was launched in May 2018, and the small molecule and multi-target receptor tyrosine kinase inhibitor androtinib hydrochloride capsule (focovir) of Zhengda Tianqing was launched in the market for the treatment of advanced or metastatic non-small cell lung cancer Enrotinib hydrochloride capsule is an innovative drug independently developed by Zhengda Tianqing, and has been approved for listing through the priority review and approval process 2 the first domestic neuropathic pain topical patch lidocaine gel paste was approved for sale in the first half of 2018 The drug lidocaine gel paste developed by Affiliated Companies Beijing TAD pharmaceutical Limited by Share Ltd has been approved for 3.1 years The product has been monitored for four years The drug is listed as the first-class recommended drug by the clinical guidelines of the United States, Europe, China and other places The approval of the drug also marks that the first external treatment patch in the field of neuropathic pain in China will officially go on the market, filling the domestic gap 3 In May 2018, the first generic acetic acid ganaric injection was approved, and the first generic acetic acid ganaric injection (Qingle) developed by Zhengda Tianqing was approved in China The product was developed and produced by mosadong, with the trade name of Orgalutran, and entered China in June 2013 According to the public information, since its listing, the sales trend of ganirick has been good With the liberalization of the two child policy and the continuous growth of the population's childbearing age, the domestic market of ganirick will be more promising 4 Runzhong (entecavir dispersible tablets) passed the consistency evaluation in March 2018, and Runzhong (entecavir dispersible tablets) passed the consistency evaluation As one of Zhengda Tianqing's fist products, Runzhong quickly occupied the market with its advantages of accurate efficacy and appropriate price, and rose to be the main product of anti HBV drugs in China Its market share in 2017 was 44% At present, the dispersible tablets of Jiangxi Qingfeng have also passed the consistency evaluation, and they are in the lead 5 Irbesartan hydrochlorothiazide tablets passed the consistency evaluation in March 2018, and irbesartan hydrochlorothiazide tablets passed the consistency evaluation Irbesartan hydrochlorothiazide tablets are suitable for patients with essential hypertension who can not effectively control blood pressure with irbesartan alone or hydrochlorothiazide alone According to the 2017 annual report, the sales volume of elanpine in 2017 was 634 million yuan, up 17.9% year on year To some extent, the market performance has been catching up with the original research There are 9 enterprises and 4 tablet manufacturers with approval documents of the drug in the domestic market At present, there are 3 enterprises applying for conformity assessment, of which 2 have passed 6 Xijia (olmesartan ester tablet) passed the consistency evaluation in March 2019, Xijia (olmesartan ester tablet) passed the consistency evaluation, olmesartan ester is a new generation of angiotension Ⅱ receptor inhibitor, which has the characteristics of long-term action, good antihypertensive effect, and oral free from food influence Because of its superior efficacy and safety performance, the drug has been listed as the first-line treatment drug for hypertension in the guidelines for prevention and treatment of hypertension in China and the guidelines for rational use of drugs for hypertension, and has been included in the 2017 new national medical insurance catalog 7 GANZE (entecavir capsule) passed the consistency evaluation in March 2019, and GANZE (entecavir capsule) passed the consistency evaluation Entecavir is a guanine nucleoside analogue for the treatment of hepatitis B compared with other drugs, it has the characteristics of high virus clearance rate, high drug resistance barrier and good drug safety The drug is the first-line treatment of hepatitis B recommended by the guideline for the prevention and treatment of chronic hepatitis B in China According to the data of minenet, the total domestic sales of entecavir in 2017 was 10.14 billion yuan.